Potential therapeutic roles for antibody mixtures

Area of Science:

• Biotechnology
• Immunology
• Pharmacology

Background:

• Recombinant monoclonal antibodies (rMAbs) and related biologics (ADCs, Fc fusion proteins, antibody fragments) are successful human therapeutics.
• Hundreds of these molecules are in clinical trials, with new formats like single-chain Fvs and bispecific antibodies under investigation.
• The established success of small molecule drug combinations and intravenous immunoglobulins provides a precedent for therapeutic biologic combinations.

Discussion:

• The therapeutic landscape is expanding beyond intact rMAbs to include diverse antibody formats and Fc fusion proteins.
• New antibody fragments and engineered constructs (e.g., scFvs, diabodies, bispecific antibodies) are being developed as monotherapeutics.
• The development of combinations of biologics, including antibody mixtures, is an emerging area driven by pharmaceutical companies.

Key Insights:

• The success of rMAbs and other biologics necessitates exploring new therapeutic modalities.
• Polypharmacology, the use of multiple drugs, is a proven strategy for treating complex diseases.
• The development of antibody mixtures represents a significant advancement in therapeutic biologic strategies.

Outlook:

• Investigating broader combinations of therapeutic biologics is a logical next step.
• Combinations of antibody mixtures are actively being explored by biotechnology companies.
• This approach holds potential for treating various human diseases, including cancer and autoimmune conditions.